Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SYS-6002 by Corbus Pharmaceuticals for Solid Tumor: Likelihood of Approval
SYS-6002 is under clinical development by Corbus Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of Corbus Pharmaceuticals's SYS-6002?
SYS-6002 is a monoclonal antibody conjugated commercialized by Corbus Pharmaceuticals, with a leading Phase II program in Solid Tumor. According...